Alzheimer disease: Protective factors

American Journal of Clinical Nutrition

Volumn 71, Issue 2, 2000, Pages

  Nourhashémi, Fati ^b   Gillette Guyonnet, Sophie ^b   Andrieu, Sandrine ^b   Ghisolfi, Anne ^b   Ousset, Pierre Jean ^b   Grandjean, Hélène ^b   Grand, Alain ^b   Pous, Jacques ^b   Vellas, Bruno ^a   Albarède, Jean Louis ^b  

^a CHU PURPAN   (France)

^b NONE

Author keywords

Alzheimer disease; Estrogen; Homocysteine; Nonsteroidal antiinflammatory drugs; Nutrition

Indexed keywords

CONJUGATED ESTROGEN; CYANOCOBALAMIN; ESTRADIOL; ESTROGEN; FOLIC ACID; FREE RADICAL; HOMOCYSTEINE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOXINE; VITAMIN;

ALZHEIMER DISEASE; COGNITION; CONFERENCE PAPER; DIET THERAPY; ESTROGEN THERAPY; HUMAN; HYPOTHESIS; INFLAMMATION; NUTRITIONAL STATUS; OXIDATIVE STRESS;

EID: 0033966803     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/71.2.643s     Document Type: Conference Paper

References (102)

1. Schneider EP. The aging of America: impact on health care costs. JAMA 1990;263:2335-40.
2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics Society. JAMA 1997;278: 1363-71.
3. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76:465-79.
4. McGeer PL, McGeer EG. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 1998;12(suppl):S1-6.
5. MacKenzie IRA, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer pathology in aging. Neurology 1998;50:986-90.
6. Uchihara T, Akiyama H, Kondo H, Ikeda K. Activated microglial cells are colocalized with perivascular deposits of amyloid-beta protein in Alzheimer's disease brain. Stroke 1997;28:1948-50.
7. Netland EE, Newton JL, Majocha RE, Tate BA. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging 1998;19:201-4.
8. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992;42:447-9.
9. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15:335-41.
10. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol 1985;121:414-21.
11. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-707.
12. Li G, Shen YC, Chen CH, Zhau YW, Silverman JM. A case control study of Alzheimer's disease in China. Neurology 1992;42:1481-2.
13. Anonymous. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-80.
14. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of cotwin control study. Neurology 1994;44:227-32.
15. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-74.
16. Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989;28:86-8.
17. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037 (letter).
18. Beard CM, Kokman E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer's disease. Lancet 1991;337:1426 (letter).
19. Myllykangas-Luosujarvi R, Isomaki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 1994;33:501-2.
20. Andersen K, Launer LJ, Ott A. Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995;45:1441-5.
21. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-5.
22. Corrada M, Stewart W, Kawas C. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. Neurology 1996;46:A433 (abstr).
23. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
24. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
25. Bruce-Jones PNE, Crome P, Kalra L. Indomethacin and cognitive function in healthy elderly volunteers. Br J Clin Pharmacol 1994;38:45-51.
26. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982;25:1013-5.
27. Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res 1998;54:1-6.
28. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997;48(suppl):S36-41.
29. Eberling JL, Jagust WJ, Reed BR, Baker MG. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging 1992;13:483-91.
30. Aronson MK, Ooi WL, Morgenstern H, et al. Women, myocardial infarction, and dementia in the very old. Neurology 1990;40:1102-6.
31. Berlinger WG, Potter JF. Low body mass index in demented outpatients. J Am Geriatr Soc 1991;39:973-8.
32. Meldrum DR, Davidson BJ, Tataryn IV, Judd HL. Changes in circulating steroids with aging in post menopausal women. Obstet Gynecol 1981;57:624-8.
33. Buckwalter JG, Schneider LS, Wilshire TW, Dunn ME, Henderson VW. Body-weight, estrogen and cognitive functioning in Alzheimer's disease: an analysis of the Tacrine study-group data. Arch Gerontol Geriatr 1997;24:261-7.
34. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-9.
35. Lerner A, Cole R, Debanne S, et al. Immunological and endocrine conditions in an Alzheimer's disease case-control study. Neuroepidemiology 1995;14:307 (abstr).
36. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15:335-41.
37. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-74.
38. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-7.
39. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
40. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-7.
41. Morrison A, Resnick S, Corrada M, Zonderman A, Kawas C. A prospective study of estrogen replacement therapy and risk of developing Alzheimer's disease in the Baltimore longitudinal study of aging. Neurology 1996;46(suppl):A435-6.
42. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
43. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83:979-83.
44. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-95.
45. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by gonadotrophin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996;81:2545-9.
46. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav 1995;29:312-21.
47. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-41.
48. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimer disease. Psychoneuroendocrinology 1996;21:421-30.
49. Caldwell BM. An evaluation of psychological effects of sex hormone administration in aged women. J Gerontol 1954;9:168-74.
50. Kantor HI, Michael CM, Shore H. Estrogen for older women, a three year study. Am J Obstet Gynecol 1973;116:115-8.
51. Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia - Alzheimer's disease type and estrogen. Horm Metab Res 1995;27:204-7.
52. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-45.
53. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989;34:521-5.
54. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994;41:361-71.
55. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimers disease. Neurology 1996;46:1580-4.
56. Wickelgren I. Estrogen stakes claim to cognition. Science 1997; 276:675-8.
57. André G. Estrogènes et maladie d'Alzheimer: les mécanismes d'action. (Estrogen and Alzheimer disease: the mechanisms of action.) Reprod Hum Horm 1996;9:145-50 (in French).
58. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid B peptide toxicity in hippocampal neurons. J Neurochem 1996; 66:1836-44.
59. Yaffe K, Sawaya G, Lieburg I, Grady D. Estrogen therapy in postmenopausal women. Effect on cognitive function and dementia. JAMA 1998;279:688-95.
60. Ott A, Breteler MMB, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310:970-3.
61. Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease. Results from EURODEM pooled analyses. Neurology 1999;52:78-84.
62. Jaendel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989;35:275-82.
63. Frey WH, Najarian MM, Kumar KS. Endogenous Alzheimer's brain factor and oxidised glutathione inhibit antagonist binding to the muscarinic receptor. Brain Res 1996;714:87-94.
64. Masoro EJ. Dietary restriction and aging. J Am Geriatr Soc 1993; 41:994-9.
65. Nolen G. Effects of various restricted dietary regimens on the growth, health, and longevity of albino rats. J Nutr 1972;102:1477-94.
66. Masoro EJ. Food restriction in rodents: an evaluation of its role in the study of aging. J Gerontol Biol Sci 1988;43:B59-64.
67. Moore WA, Davey VA. Weindruch R, Walford R, Ivy GO. The effect of caloric restriction on lipofuscin accumulation in mouse brain with age. Gerontology 1995;41:173-85.
68. Weed JL, Lane MA, Roth GS, Speer DL, Ingram DK. Activity measures in rhesus monkeys on long-term calorie restriction. Physiol Behav 1997;62:97-103.
69. Ingram DK, Cutler RG, Weindruch R. Dietary restriction and aging: the initiation of a primate study. J Gerontol 1990;45:B148-63.
70. Yu BP, Yang R. Critical of the free radical theory of aging. Ann N Y Acad Sci 1996;786:1-11.
71. Velthuis-te Wierik EJ, van den Berg H, Schaafsma G, Hendricks HF, Brouwer A. Energy restriction, a useful intervention to retard human ageing? Results of a feasibility study. Eur J Clin Nutr 1994;48:138-48.
72. Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983;249:2917-21.
73. Tucker DM, Penland JG, Sandstead HH, Milne DB, Heck DG, Klevay LM. Nutrition status and brain function in aging. Am J Clin Nutr 1990;52:93-102.
74. Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306-14.
75. La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. Am J Clin Nutr 1997;65:20-9.
76. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71(suppl):614S-20S.
77. McCaddon A, Kelly CL. Familial Alzheimer's disease and vitamin B12 deficiency. Age Ageing 1994;23:334-7.
78. Hector M, Burton JR. What are the psychiatric manifestations of vitamin B12 deficiency ? J Am Geriatr Soc 1988;36:1105-12.
79. Ikeda T, Furukawa Y, Mashimoto S, Takahashi K, Yamada M. Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer's disease. Acta Psychiatr Scand 1990;82:327-9.
80. Levitt AJ, Karlinsky H. Folate, vitamin B12 and cognitive impairment in patients with Alzheimer's disease. Acta Psychiatr Scand 1992;86:301-5.
81. Kristensen MO, Gulmann NC, Christensen JEJ, Ostergaard K, Rasmussen K. Serum cobalamin and methylmalonic acid in Alzheimer dementia. Acta Neurol Scand 1993;87:475-81.
82. Basun H, Fratiglioni L, Winblad B. Cobalamin levels are not reduced in Alzheimer's disease: results from a population based study. J Am Geriatr Soc 1994;42:132-6.
83. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci 1997;52:M76-9.
84. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
85. Bell IR, Edman JS, Selhub J, et al. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand 1992;86:386-90.
86. Diaz-Arrastia R. Hyperhomocysteinemia: a new risk factor for Alzheimer disease? Arch Neurol 1998;55:1-2.
87. Lauque S, Wegner A, Ousset PJ, et al. Etude comparative des apports alimentaires et des fonctions neuro-psychologiques explorées par le test de code de Wais. [Comparative study on nutritional intake and cognitive functions (WAIS code).] Age Nutr 1995;6:68-72 (in French).
88. Perrig WJ, Perrig P, Stèhelin B. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997;45:718-24.
89. Ortega RM, Requejo AM, Andres P, et al. Dietary intake and cognitive function in a group of elderly people. Am J Clin Nutr 1997;66:803-9.
90. Riviere S, Birlouez-Aragon I, Nourhashemi F, Vellas B. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatr 1998;13:749-54.
91. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
92. Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:121-6.
93. Orgogozzo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol 1997;153:185-92.
94. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late onset familial Alzheimer disease. Proc Nat Acad Sci U SA 1993;90:1977-81.
95. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
96. Chartier-Harlin MC, Parfitt M, Legrain S, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor sporadic early and late-onset forms of Alzheimer's disease. Hum Mol Genet 1994;3:569-74.
97. Farrer LA, Cupples A, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997;278: 1349-56.
98. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1997;17:525-30.
99. Corder EH, Saunders AM, Rish NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-4.
100. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer disease. Annu Rev Med 1996;47:387-400.
101. La Rue A, Haaland KY. Neurological, psychological, cognitive function. In: Garry PJ, Owen GM, Eldridge TO, eds. The New-Mexico Aging Process Study 1980-1997. Albuquerque, NM: University of New Mexico Press, 1997:210-40.
102. O' Hara R, Yesavage J, Kraemer HC, et al. The APOE ∈4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc 1998;46:1493-8.